Abstract
Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have